Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2010; 5(5): e10690.
Published online 2010 May 18. doi:  10.1371/journal.pone.0010690
PMCID: PMC2872660

Development of an Acute and Highly Pathogenic Nonhuman Primate Model of Nipah Virus Infection

Steven Jacobson, Editor


Nipah virus (NiV) is an enigmatic emerging pathogen that causes severe and often fatal neurologic and/or respiratory disease in both animals and humans. Amongst people, case fatality rates range between 40 and 75 percent and there are no vaccines or treatments approved for human use. Guinea pigs, hamsters, cats, ferrets, pigs and most recently squirrel monkeys (New World monkey) have been evaluated as animal models of human NiV infection, and with the exception of the ferret, no model recapitulates all aspects of NiV-mediated disease seen in humans. To identify a more viable nonhuman primate (NHP) model, we examined the pathogenesis of NiV in African green monkeys (AGM). Exposure of eight monkeys to NiV produced a severe systemic infection in all eight animals with seven of the animals succumbing to infection. Viral RNA was detected in the plasma of challenged animals and occurred in two of three subjects as a peak between days 7 and 21, providing the first clear demonstration of plasma-associated viremia in NiV experimentally infected animals and suggested a progressive infection that seeded multiple organs simultaneously from the initial site of virus replication. Unlike the cat, hamster and squirrel monkey models of NiV infection, severe respiratory pathology, neurological disease and generalized vasculitis all manifested in NiV-infected AGMs, providing an accurate reflection of what is observed in NiV-infected humans. Our findings demonstrate the first consistent and highly pathogenic NHP model of NiV infection, providing a new and critical platform in the evaluation and licensure of either passive and active immunization or therapeutic strategies for human use.


Nipah virus (NiV) is a recently recognized viral zoonotic pathogen of the family Paramyxoviridae that is distinguished by its ability to cause fatal disease in both animal and human hosts. NiV along with Hendra virus (HeV) comprise the new genus Henipavirus (reviewed [1], [2]). NiV was first identified during an outbreak of severe encephalitis in Malaysia and Singapore in 1998–99 that involved hundreds of people and more than 100 deaths, with pigs serving as the intermediate amplifying host [3], [4]. Since 1998 there have been more than a dozen recognized occurrences of human NiV infection, primarily in Bangladesh and India (reviewed [5]) with the two most recent outbreaks in March 2008 [6] and January 2010 [7]. In the majority of subsequent spillover events, the mortality rate among humans has been higher (~75%) along with evidence of multiple rounds of person-to-person transmission [8].

Several species of fruit bats of the Pteropus genus (flying foxes) appear to be the principle natural reservoirs of both NiV and HeV (reviewed [5]) but serological evidence of NiV or Nipah-like virus infection has recently been reported in several additional frugivorous and insectivorous bats [9], [10]. NiV has been isolated from bat urine and partially eaten fruit [11], [12] and direct transmission of NiV from flying foxes to humans from contaminated food sources has been suggested [13], [14]. The Centers for Disease Control and Prevention (CDC) and the National Institute of Allergy and Infectious Diseases (NIAID) have classified NiV as a select agent with the potential for causing significant morbidity and mortality in humans and major economic and public health impacts. Consequently, work with live virus requires Biosafety Level 4 (BSL-4) containment.

Host cell infection by NiV requires two membrane-anchored envelope glycoproteins; the attachment glycoprotein (G) which binds receptor and the fusion (F) glycoprotein which facilitates virus-host cell membrane fusion [2]. NiV G lacks hemagglutinin and neuraminidase activities and F is a typical class I fusion glycoprotein [15]. Recently, ephrin-B2 and ephrin-B3 ligands were identified as receptors employed by the henipaviruses for infection [16], [17], [18], [19]. For paramyxoviruses, the majority of virus-neutralizing antibody is directed towards these two envelope glycoproteins with the attachment glycoprotein serving as the dominant target antigen [20], [21], [22]. Indeed, recombinant soluble G from HeV and NiV has been successfully employed as a subunit vaccine in a NiV challenge model in the cat [23], [24], and evidence of passive antibody protection against NiV and HeV challenge in the hamster has been reported [25], [26], [27]. More recently a cross reactive, neutralizing and fully human monoclonal antibody has been shown to be an effective post-exposure therapeutic against NiV in a new ferret model [28]. However, there are currently no vaccines or therapeutic modalities approved for the prevention or treatment of henipavirus infections in humans.

The development and characterization of suitable animal models for henipavirus infection is essential for understanding their pathogenic characteristics and mechanisms as well as fulfilling the critical needs for the in vivo evaluation of potential antiviral modalities for human use. To date, guinea pigs, golden hamsters, cats, ferrets and pigs have been evaluated as experimental animal models of human NiV infection (reviewed[5], [29], [30]). The restriction of live henipavirus experimentation to BSL-4 containment has significantly hampered the development of henipavirus countermeasures in a rapid and systematic fashion. In addition, the U.S. Food and Drug Administration (FDA) has implemented the Animal Efficacy Rule which came into effect in 2002. This rule specifically applies to the development of therapeutic products when human efficacy studies are not possible or ethical, such as is often the case with highly virulent emerging pathogens like NiV. Essentially, this rule allows for the evaluation of vaccines or therapeutics using data derived from studies carried out in at least two animal models. Although the ferret seems to be the most accurate animal model developed thus far, the licensure of any antiviral therapeutic for NiV will likely also require an evaluation of NiV pathogenesis in nonhuman primates. However, there has been little experimentation directed towards the evaluation of henipavirus infection outcomes in nonhuman primates. Here we describe a new animal model of acute NiV infection and associated disease in the African green monkey (AGM).


Nipah Virus Infection and Pathogenesis in African Green Monkeys

There is no information presently available on the sequence homology between the human and African green monkey (AGM) (Chlorocebus aethiops) ephrin-B2 or ephrin-B3 receptors. However, we reasoned that the human and AGM ephrins should be quite similar given the high amino acid sequence homology across a variety of vertebrate species. While none of the henipaviruses have been specifically adapted to a simian host or for usage of a simian ephrin receptor protein NiV and HeV replicate to very high titers (>107) in Vero cells which are derived from AGMs. We first performed a challenge study in three AGMs (Subjects 1–3) with doses ranging from 7.0×103 to 1.3×106 plaque forming units (pfu) of NiV by intratracheal (i.t.) and oral delivery. In this initial experiment, the monkeys appeared highly susceptible to acute disease caused by exposure to NiV (Table 1). All three animals became severely ill with symptoms highly consistent with human NiV infection and disease [31], [32], [33], [34], [35].

Table 1
Clinical description and outcome of Nipah virus challenged monkeys.

Based on these initial findings, a second experiment was carried out in five AGMs (Subjects 4–8). NiV was inoculated i.t. and doses ranged from 2.5×103 to 6.5×104 pfu (Table 1). Together, these data indicated that NiV lethality in AGMs occurred within 9 to 12 days after virus infection with an i.t. or i.t and oral exposure with doses ranging from ~2.5×103 pfu to ~1.3×106 pfu of NiV (Table 1). All animals in these susceptibility studies (Subjects 1–8) developed a severe acute-respiratory-distress-syndrome (ARDS)-like disease, associated with copious amounts of sanguinous fluid and froth (Figure 1A). Gross pathological examination revealed severely inflated and enlarged lungs with multifocal areas of congestion and hemorrhage (Figure 1B). Immunohistochemical and histopathological examination showed significant amounts of polymerized fibrin and NiV antigen (Figure 1C and 1D). Endothelial syncytial cells were particularly prominent in tissues of most animals and vasculitis and its sequelae were the most common lesions observed. NiV antigen was present in endothelial and arterial smooth muscle cells in most tissues examined with lung appearing to be the most severely affected organ (Figure 1E). Syncytial cells were also prominent in a variety of other tissues including spleen, a hallmark feature of these paramyxoviruses and also seen in naturally and experimentally infected animals (Figure 2) [24], [36], [37]. NiV is also known for its appearance and shedding in the urine of infected animals including bats, and the bladders of infected monkeys were involved showing inflammation and hemorrhage and high levels of NiV antigen (Figure 3). Immunohistochemical and histopathological analysis revealed the presence of NiV antigen, predominantly in endothelial cells and smooth muscle cells, along with associated pathology in a wide of variety tissues, including the tongue, salivary gland, larynx and trachea, heart, gall bladder, kidneys, sex organs, pituitary and adrenal glands, stomach, small and large intestine, and skeletal muscles (data not shown).

Figure 1
NiV pathogenesis in the African green monkey.
Figure 2
NiV infection and pathogenesis in the spleen.
Figure 3
NiV infection and pathogenesis in the urinary bladder.

In addition and of significant importance, most animals showed evidence of neurologic disease (Table 1 and Figure 4). Severe congestion with evidence of meningeal hemorrhaging and edema was observed (Figure 4A). NiV antigen was detected in endothelial cells in brain of all animals in this study (Subjects 1, 3–8), example shown in Figure 4B and 4C. In addition, most animals also showed NiV infection of neurons (Figure 4D–F), often widespread in the brainstem. Further, because of the observed unique respiratory involvement of the acute NiV infection in the monkeys, we sought approval for bringing in a portable X-ray device into the BSL-4 and subsequently carried out a series of X-ray images on one animal with signs of acute NiV disease (Subject 3; see Table 1). Here, changes in radiographs were evident by day 7 when ventrodorsal view showed developing pneumonia or congestion. At day 10 and 11 congestion and pneumonia with infiltrates on the lung fields were evident. At day 11 the heart appeared larger and rounder suggestive of pericardial effusion (Figure 5).

Figure 4
NiV infection and pathogenesis in the brain.
Figure 5
Progressive NiV pathogenesis in the African green monkey analyzed by X-ray autoradiography.

A single animal exposed to a low dose of ~7×103 pfu of NiV (Subject 2) became severely ill on day 4 and remained clinically severely ill until day 18 at which time the animal began to recover. Together, these data indicated that NiV lethality in AGMs occurred within 9 to 12 days after virus infection with an i.t. or i.t and oral exposure with doses ranging from ~2.5×103 pfu to ~1.3×106 pfu of NiV (Table 1).

Nipah Viral Loads and Tissue Tropism in African Green Monkeys

To examine the extent of virus replication and tissue tropism among monkeys challenged with NiV, the relative quantity of the NiV RNA was measured in blood as well as swabs obtained from pharyngeal, rectal, and vaginal (where appropriate) surfaces sampled the course of infection. In addition, multiple tissues were harvested from NiV-challenged monkeys at the time of necropsy and the relative quantity of NiV RNA was measured. The relative quantity of NiV RNA was determined utilizing a Taqman probe that targets the NiV nucleoprotein (N) gene and detects cDNA derived from both genomic and positive sense RNA [23]. Figure 6 shows a comparison of the NiV RNA levels detected at various times post infection from a series of whole blood samples and blood components collected during the initial AGM NiV challenge study. NiV RNA detection corresponded closely with the onset of clinical illness and the progression of the disease. Viral RNA was detected in the plasma of all challenged animals and is the first clear demonstration of plasma-associated viremia in NiV experimentally infected animals (Figure 6). Virus was also isolated from some plasma and whole blood samples when available (Table 2). Whole blood, plasma, and PBMC were also sampled periodically over a 12 day period following NiV challenge in the 2.5×103 to 6.5×104 pfu i.t. group (Subjects 4–8). Here, only Subject 7 had detectible viral RNA at day 7 similar to the low and variable detection of RNA observed in Subjects 1 and 3 (Figure 6), all other samples from Subjects 4, 5, 6, and 8 were negative (data not shown). Together, these data suggest the virus can spread in the host via a hematagenous route in the cell-free blood compartment. In almost all cases where NiV N RNA was detected, the highest RNA levels corresponded with the day of euthanasia or death of the animal. Subject 2 had an initial peak of viremia on day 10 during a period of severe clinical illness (Table 1), but by day 17 started to recover from disease. Interestingly, although viremia was detected again on day 21, this animal made a full recovery and was completely protected from a second NiV challenge 38 days later (data not shown). For the remaining animals, the correlation of peak viral RNA in the blood and severe illness suggests a progressive infection that seeded multiple organs simultaneously from the initial site of virus replication.

Figure 6
The normalized relative quantity of NiV RNA detected among blood samples from NiV-infected AGMs.
Table 2
Viral load in African green monkeys after Nipah virus challenge.

Over the course of the initial study, swab samples from the nasal passages, pharyngeal surface, rectum, and vaginal mucosa (where appropriate) were also collected and assayed. No viral RNA was detected in vaginal samples or from swab samples obtained from Subject 2 (low challenge dose). Figure 7 shows a comparison of the relative quantity of NiV RNA detected among the remaining swab samples. Viral RNA was most often detected in nasal and throat swabs. Longitudinal periodic detection (Subject 3: Figure 7A) was similar to observations made in the cat model. The detection of viral RNA in Subject 1 swab samples (Figure 7B) was co-incident with an increased burden of virus in blood and tissue samples and severe acute disease. Together, these results indicate virus can be detected at multiple mucosal surfaces of the respiratory system.

Figure 7
The relative quantity of NiV RNA detected by Taqman RT-PCR.

The gross pathology and immunohistochemistry staining of tissues from the infected AGM subjects suggest spread of the virus occured rapidly (3–4 days post-infection) to numerous organ systems. Detection of viral RNA among a variety of tissue samples following necropsy (Subjects 1, 3–8) demonstrated the virus can be found in virtually every organ system sampled at the time of death depending on the animal examined (Figure 8). Viral RNA was highest among the spleen, adrenal gland, axillary lymph node, and pancreas. Other tissues with high levels of viral RNA included the brain, spleen and kidney. Further study is required to establish the time course of infection of these organ systems. Viral RNA was detected in only a single lung sample even though viral antigen can clearly be demonstrated in all of the lungs from challenged animals. The extensive lung pathology, severe necrosis and fibrin deposition, observed at the time of necropsy, likely contributed to the inability to detect viral RNA or isolate 18S rRNA from these sites.

Figure 8
The relative quantity of NiV RNA detected by Taqman RT-PCR among AGM tissue samples obtained at necropsy from all Subjects except Subject 2 (survived).


In the present study, we investigated a new nonhuman primate model of acute NiV infection and pathogenesis using AGMs. These are the first experiments conducted in any large nonhuman primate species using a henipavirus (NiV). Unlike the previously reported NiV cat, hamster and squirrel monkey models, severe respiratory pathology, neurological disease and generalized vasculitis all manifested in NiV-infected monkeys, providing an accurate reflection of what is observed in NiV-infected humans. Here, we have observed a uniformly lethal disease with doses as low as ~2×104 pfu. A wider experiment now needs to be conducted to accurately define the minimal lethal infectious dose of NiV in this new model. Gross pathological findings revealed widespread tissue distribution of NiV with findings quite similar to those reported in NiV-infected humans, characterized as a systemic vascular disease with extensive inflammation in the respiratory epithelium associated with viral antigen and endothelial syncytia, and the brain also affected with vascular lesions.

A number of NiV RNA positive swabs from rectal, throat and nasal-oral samples were identified suggesting the possibility of virus-shedding. In addition, heavy involvement of virus infection and replication was seen in the bladder, and henipaviruses have been shown to be shed in urine. Viral shedding at the mucosal surfaces may facilitate the transmission of the virus among mammalian species in the absence of the reservoir host, including among humans. Person-to-person transmission documented during repeated epidemics in Bangladesh can potentially be explained as resulting from the aerosolization of viral particles shed at the surface of the pharynx. Future experimentation focusing on the amounts and location of infectious virus shedding will be important.

We isolated virus from subjects 1 through 5 from plasma or whole blood samples. These data indicate a low-level viremia can be detected prior to the advancement of the disease in the animal. Detection of the virus principally among plasma samples of the animals supports the PCR data in showing the virus likely disseminates to multiple organ systems from the initial site of infection by hematogenous spread in the cell-free blood component. Virus isolation from blood and plasma samples was consistently difficult when compared to the robust results detected by PCR. This phenomenon is not, however, unexpected as RT-PCR is far more sensitive than virus plaque assay. Further, detection of virus in RT-PCR is not limited to infectious particles, but also measures non-infectious particles and free viral RNA among samples. As anticipated from those observations, we also measured a wide presence of NiV RNA across a variety of tissue samples. Indeed, one of the most encouraging signs from the studies reported here was the presence of NiV RNA in neuronal tissue in conjunction with immunohistochemical staining of viral antigen in endothelial cells in the brain.

This is the first report demonstrating an acute, highly pathogenic and lethal NiV infection model in a nonhuman primate, the AGM, and provides a path for the establishment of a BSL-4-restricted primate animal model for NiV. There are currently no approved antiviral drugs or vaccines available for the henipaviruses, and neither virus productively infects or causes disease in typical small animal models, including mice or rabbits [5], [29]. Recently, the susceptibility of squirrel monkeys to NiV was examined [38]. Although some squirrel monkeys demonstrated limited similarities to NiV pathogenesis in humans only 50% of challenged animals exhibited any clinical signs with most remaining well, even following intranasal or intravenous delivery of doses as high as 107 pfu of NiV. Among other smaller animal models explored, the response to either NiV or HeV in guinea pigs has been reported to be highly variable. Although a generalized vascular disease was observed with HeV in guinea pigs there was little or no pulmonary edema [39], [40]. Infection of guinea pigs with high doses of NiV (107 PFU) showed only transient clinical signs followed by recovery [41] and another study using a high dose of virus by intraperitoneal administration produced disease in less than half of challenged animals [42]. There have also been some potential limitations noted in two other well-characterized animal models, the cat and hamster [24], [39], [41], [43], [44], particularly no overt CNS pathogenesis or respiratory disease, respectively. Only the recently described ferret model of NiV infection exhibited both severe respiratory and neurological disease and generalized vasculitis in which the underlying pathology closely resembled NiV-mediated disease seen in humans [28].

In summary, our findings reported here provide evidence of a new, consistent and highly pathogenic, NHP model of NiV infection that will be critical for future work on this important emerging pathogen. Based on all available reports to date, our NHP model of acute NiV infection appears to provide one of the best reproductions of human pathology observed. Together, the AGM and ferret models of NiV infection appear to be the best available platforms to comply with the “two animal rule” and will be critical in the evaluation of both passive and active immunization or therapeutic strategies for human use [45], [46].

Materials and Methods

Ethics Statement

Animal studies were performed in BSL-4 biocontainment at USAMRIID and were approved by the USAMRIID Laboratory Animal Use Committee. Animal research was conducted in compliance with the Animal Welfare Act and other Federal statutes and regulations relating to animals and experiments involving animals and adheres to the principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 1996 [47]. The facility where this research was conducted is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.


NiV was obtained from a patient from the 1998–99 outbreak in Malaysia [48]. NiV stocks were prepared by three passages on Vero cells (stock virus titer 1×107 pfu/ml).

Animal Studies

An environmental enrichment strategy for animals was unrestricted and provided by toys, treats, fresh fruits and vegetables. Animals were monitored daily for health, humane treatment and husbandry conditions, and acclimated to a BSL-4 animal room for a minimum of 5 days before protocol commencement. All procedures were carried out with sedated animals and all NiV-infected animals were closely monitored for signs of clinical illness and a general distress and a humane endpoint scoring system was used to determine study endpoint.

Eight henipavirus-seronegative adult African green monkeys (AGM) (Chlorocebus aethiops) (5–7 kg) were used for these studies. Animals were exposed to NiV by intratracheal (i.t.) or i.t. and oral routes with a range of virus doses as shown in Table 1. All animals were closely monitored for evidence of clinical illness (temperature, respiration, anorexia, dehydration, central nervous system disturbances, reduced activity and changes in behavior, and changes in complete blood count and chemistry) following NiV challenge. Physical exams and blood and swabs (nasal, oral, rectal) were collected before NiV challenge and at 3, 4, 7, 10, and 14, days after NiV challenge.

Hematology and Serum Biochemistry

Total white blood cell counts, white blood cell differentials, red blood cell counts, platelet counts, hematocrit values, total hemoglobin, mean cell volume, mean corpuscular volume, and mean corpuscular hemoglobin concentration were determined from blood samples collected in vacutainer tubes containing EDTA, by using a laser-based hematologic Analyzer (Coulter Electronics, Hialeah, FL, USA). Serum samples were tested for concentrations of albumin (ALB), amylase (AMY), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), glucose (GLU), cholesterol (CHOL), total protein (TP), total bilirubin (TBIL), blood urea nitrogen (BUN), and creatinine (CRE) by using a Piccolo Point-Of-Care Blood Analyzer (Abaxis, Sunnyvale, CA, USA).

Sample Collection and RNA Isolation

Swab (oral, nasal, rectal, and vaginal) and blood samples were collected as described above. Tissue samples (liver, spleen, kidney, adrenal, lung, lymph node, pancreas, brain, and bone marrow) were harvested from animals at the time of necropsy. Blood samples were collected in vacutainer tubes containing EDTA and a portion of each was separated into individual blood components (plasma, granulocytes, peripheral blood mononuclear cells, and lysed red blood cells) by gradient centrifugation using Ficoll 400 (Sigma-Aldrich, St. Louis, MO) at 400×g for 45 min at room temperature. Tissue samples were ground in TriPure reagent (Roche Applied Sciences, Indianapolis, IN) at a concentration of 10% w/v. Blood samples were immediately diluted in TriPure Isolation Reagent at a ratio of 1 part plasma or swab sample to 4 parts TriPure reagent, 1 part whole blood, granulocytes, lysed red blood cells, or PBMC sample to 8 parts TriPure reagent. TriPure diluted samples were stored at −80°C. All samples were thawed at room temperature prior to RNA isolation. Total RNA was isolated from each TriPure dilute sample and each sample was resuspended with 35 µl of ultrapure water treated with 0.1% diethylpyrocarbonate (DEPC; Invitrogen, Carlsbad, CA). Samples of purified RNA were stored at −20°C.

TaqMan PCR

TaqMan PCR was performed using the primer sets and probes as previously described [23]. Samples were amplified with a GeneAmp 7500 Sequence Detection System (Applied Biosystems). Ct values representing NiV RNA in samples were analyzed and data recorded as relative quantity or relative quantity per ml of sample.

Virus Isolation

Virus isolation was only attempted from specimens positive for NiV RNA by PCR. Virus titration was performed by plaque assay on Vero cells as previously described [49]. Briefly, increasing 10-fold dilutions of the samples were adsorbed to Vero monolayers in duplicate wells (0.2 ml per well); thus, the limit for detection was 25 pfu/ml.

Histopathology and Immunohistochemistry

A complete necropsy was performed on all animals. Tissue samples of all major organs were collected from each monkey for histopathologic and immunohistochemical examination and were immersion-fixed in 10% neutral buffered formalin. Replicate sections of spleen, liver, lung, kidney, axillary lymph nodes, and inguinal lymph nodes were stained with phosphotungstic hematoxylin (PTAH) to demonstrate polymerized fibrin [50]. All immunohistochemical staining was done using an immunoperoxidase-based system (Envision+, DAKO Corporation, Carpenteria, CA). Tissue sections were pretreated with a TRIS/EDTA buffer at 97°C for 30 min and blocked with 5% normal goat serum. The primary antibody was either a rabbit anti-NiV polyclonal antibody [37] diluted 1[ratio]1000, incubated for 30 min at room temperature or a monoclonal antibody to fibrin II (NYB-T2G1, Accurate Chemical Scientific Corporation, Westbury, NY) diluted 1[ratio]100, incubated overnight. Sections were rinsed, and then exposed to a peroxidase -labeled polymer (Envision®, DAKO) for 30 min. Color development was attained by exposing tissue to 3,3′-diaminobenzidine (DAB) for 5 min and counter-stained in hematoxylin.

Electron Microscopy

Select tissues for ultrastructural examination were immersion-fixed in 4% formaldehyde plus 1% glutaraldehyde in 0.1 mol/L Millonig's phosphate buffer for transmission electron microscopy. Tissues were postfixed in 1% osmium tetroxide in 0.1 mol/L phosphate buffer, rinsed, stained with 0.5% uranyl acetate in ethanol, dehydrated in graded ethanol and propylene oxide, and embedded in Poly/Bed 812 resin (Polysciences, Warrington, PA). Ultrathin sections were cut, placed on 300-mesh nickel TEM grids, stained with uranyl acetate and lead citrate, and examined using a JEOL 1010 transmission electron microscope (JEOL Ltd., Peabody, MA) at 80 kV.

X-Ray images

X-ray images were obtained using the The MinXray model HF 100/30 portable x-ray unit (Northbrook, IL) operated at 50 kV 12 mAs at 0.40 seconds at a distance of 36 inches from the subject. Fuji Type C digital 14×17 inch cassettes were employed and processed using the Fuji Smart CR® processor (Fujifilm USA, Stamford, CT).


The authors wish to thank the USAMRIID staff for animal care and for expert technical assistance and support. Portions of this work were first presented at the American Society of Tropical Medicine and Hygiene annual meeting, New Orleans, Louisiana, December 2008. The opinions, interpretations, conclusions, and recommendations expressed in this manuscript are solely those of the authors and are not necessarily endorsed by Boston University, the U.S. Army, Uniformed Services University or the Department of Defense.


Competing Interests: The authors have declared that no competing interests exist.

Funding: This study was supported in part by the Department of Health and Human Services, National Institutes of Health, grants AI082121 and AI057159 to TWG; DE018339, DE019397 and AI071812 to JJM, and AI054715 and AI077995 to CCB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Eaton BT, Broder CC, Middleton D, Wang LF. Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol. 2006;4:23–35. [PubMed]
2. Eaton BT, Mackenzie JS, Wang L-F. Henipaviruses. In: Knipe DM, Howley PM, editors. Fields Virology. 5 ed. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 1587–1600.
3. Chua KB. Nipah virus outbreak in Malaysia. J Clin Virol. 2003;26:265–275. [PubMed]
4. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, et al. Nipah virus: a recently emergent deadly paramyxovirus. Science. 2000;288:1432–1435. [PubMed]
5. Bishop KA, Broder CC. Hendra and Nipah: Lethal Zoonotic Paramyxoviruses. In: Scheld WM, Hammer SM, Hughes JM, editors. Emerging Infections. Washington, D.C.: American Society for Microbiology; 2008. pp. 155–187.
6. Anonymous. 2008. Nipah virus, fatal - Bangladesh (03). Pro-MED (International Society for Infectious Diseases) (March 11, 2008, archive no. 20080311.0979. Available at
7. Anonymous. 2010. Nipah virus, fatal - Bangladesh: (Faridpur). Pro-MED (International Society for Infectious Diseases) (January 22, 2010, archive no. 20100122.0250. Available at
8. Gurley ES, Montgomery JM, Hossain MJ, Bell M, Azad AK, et al. Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis. 2007;13:1031–1037. [PMC free article] [PubMed]
9. Li Y, Wang J, Hickey AC, Zhang Y, Wu Y, et al. Antibodies to Nipah or Nipah-like viruses in bats, China. Emerg Infect Dis. 2008;14:1974–1976. [PMC free article] [PubMed]
10. Hayman DT, Suu-Ire R, Breed AC, McEachern JA, Wang L, et al. Evidence of henipavirus infection in West African fruit bats. PLoS ONE. 2008;3:e2739. [PMC free article] [PubMed]
11. Chua KB, Lek Koh C, Hooi PS, Wee KF, Khong JH, et al. Isolation of Nipah virus from Malaysian Island flying-foxes. Microbes Infect. 2002;4:145–151. [PubMed]
12. Reynes JM, Counor D, Ong S, Faure C, Seng V, et al. Nipah virus in Lyle's flying foxes, Cambodia. Emerg Infect Dis. 2005;11:1042–1047. [PubMed]
13. Harit AK, Ichhpujani RL, Gupta S, Gill KS, Lal S, et al. Nipah/Hendra virus outbreak in Siliguri, West Bengal, India in 2001. Indian J Med Res. 2006;123:553–560. [PubMed]
14. Luby SP, Rahman M, Hossain MJ, Blum LS, Husain MM, et al. Foodborne transmission of Nipah virus, Bangladesh. Emerg Infect Dis. 2006;12:1888–1894. [PubMed]
15. Bossart KN, Broder CC. Pöhlmann S, Simmons G, editors. Paramyxovirus Entry. Viral Entry into Host Cells. 2009. Austin, TX Landes Bioscience.
16. Bishop KA, Stantchev TS, Hickey AC, Khetawat D, Bossart KN, et al. Identification of Hendra virus G glycoprotein residues that are critical for receptor binding. J Virol. 2007;81:5893–5901. [PMC free article] [PubMed]
17. Bonaparte MI, Dimitrov AS, Bossart KN, Crameri G, Mungall BA, et al. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A. 2005;102:10652–10657. [PubMed]
18. Negrete OA, Levroney EL, Aguilar HC, Bertolotti-Ciarlet A, Nazarian R, et al. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature. 2005;436:401–405. [PubMed]
19. Negrete OA, Wolf MC, Aguilar HC, Enterlein S, Wang W, et al. Two Key Residues in EphrinB3 Are Critical for Its Use as an Alternative Receptor for Nipah Virus. PLoS Pathog. 2006;2:e7. [PMC free article] [PubMed]
20. Karron RAC, P. L. Parainfluenza Viruses. In: Knipe DM, Howley PM, editors. Fields Virology. 5 ed. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 1497–1526.
21. Carbone KM, Rubin S. Mumps Virus. In: Knipe DM, Howley PM, editors. Fields Virology. 5 ed. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 1527–1550.
22. Griffin DE. Measles Virus. In: Knipe DM, Howley PM, editors. Fields Virology. 5 ed. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 1551–1585.
23. McEachern JA, Bingham J, Crameri G, Green DJ, Hancock TJ, et al. A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine. 2008;26:3842–3852. [PubMed]
24. Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, et al. Feline model of acute Nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol. 2006;80:12293–12302. [PMC free article] [PubMed]
25. Guillaume V, Lefeuvre A, Faure C, Marianneau P, Buckland R, et al. Specific detection of Nipah virus using real-time RT-PCR (TaqMan). J Virol Methods. 2004;120:229–237. [PubMed]
26. Guillaume V, Contamin H, Loth P, Grosjean I, Courbot MC, et al. Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J Virol. 2006;80:1972–1978. [PMC free article] [PubMed]
27. Guillaume V, Wong KT, Looi RY, Georges-Courbot MC, Barrot L, et al. Acute Hendra virus infection: Analysis of the pathogenesis and passive antibody protection in the hamster model. Virology. 2009;387:459–465. [PubMed]
28. Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog. 2009;5:e1000642. [PMC free article] [PubMed]
29. Bossart KN, Bingham J, Middleton D. Targeted strategies for Henipavirus therapeutics. Open Virology Journal. 2007;1:14–25. [PMC free article] [PubMed]
30. Broder CC. Therapeutics and Vaccines against Hendra and Nipah Viruses. In: Levine M, editor. New Generation Vaccines. 4 ed. New York: Informa Healthcare USA; 2008.
31. Paton NI, Leo YS, Zaki SR, Auchus AP, Lee KE, et al. Outbreak of Nipah-virus infection among abattoir workers in Singapore [see comments]. Lancet. 1999;354:1253–1256. [PubMed]
32. Goh KJ, Tan CT, Chew NK, Tan PS, Kamarulzaman A, et al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med. 2000;342:1229–1235. [PubMed]
33. Wong KT, Shieh WJ, Kumar S, Norain K, Abdullah W, et al. Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis. Am J Pathol. 2002;161:2153–2167. [PubMed]
34. Chadha MS, Comer JA, Lowe L, Rota PA, Rollin PE, et al. Nipah virus-associated encephalitis outbreak, Siliguri, India. Emerg Infect Dis. 2006;12:235–240. [PubMed]
35. Tan CT, Chua KB. Nipah virus encephalitis. Curr Infect Dis Rep. 2008;10:315–320. [PubMed]
36. Hooper P, Zaki S, Daniels P, Middleton D. Comparative pathology of the diseases caused by Hendra and Nipah viruses. Microbes Infect. 2001;3:315–322. [PubMed]
37. Middleton DJ, Westbury HA, Morrissy CJ, van der Heide BM, Russell GM, et al. Experimental Nipah virus infection in pigs and cats. J Comp Pathol. 2002;126:124–136. [PubMed]
38. Marianneau P, Guillaume V, Wong T, Badmanathan M, Looi RY, et al. Experimental infection of squirrel monkeys with nipah virus. Emerg Infect Dis. 2010;16:507–510. [PubMed]
39. Hooper PT, Westbury HA, Russell GM. The lesions of experimental equine morbillivirus disease in cats and guinea pigs. Vet Pathol. 1997;34:323–329. [PubMed]
40. Williamson MM, Hooper PT, Selleck PW, Westbury HA, Slocombe RF. A guinea-pig model of Hendra virus encephalitis. J Comp Pathol. 2001;124:273–279. [PubMed]
41. Wong KT, Grosjean I, Brisson C, Blanquier B, Fevre-Montange M, et al. A golden hamster model for human acute Nipah virus infection. Am J Pathol. 2003;163:2127–2137. [PubMed]
42. Middleton DJ, Morrissy CJ, van der Heide BM, Russell GM, Braun MA, et al. Experimental Nipah Virus Infection in Pteropid Bats (Pteropus poliocephalus). J Comp Pathol. 2007;136:266–272. [PubMed]
43. Westbury HA, Hooper PT, Brouwer SL, Selleck PW. Susceptibility of cats to equine morbillivirus. Aust Vet J. 1996;74:132–134. [PubMed]
44. Mungall BA, Middleton D, Crameri G, Halpin K, Bingham J, et al. Vertical transmission and fetal replication of Nipah virus in an experimentally infected cat. J Infect Dis. 2007;196:812–816. [PubMed]
45. Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng YR, et al. Receptor binding, fusion inhibition and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol. 2005;79:6690–6702. [PMC free article] [PubMed]
46. Zhu Z, Bossart KN, Bishop KA, Crameri G, Dimitrov AS, et al. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis. 2008;197:846–853. [PubMed]
47. National Research Council. Guide for the care and use of laboratory animals. 1996. National Academy Press, Washington, DC.
48. Chua KB, Goh KJ, Wong KT, Kamarulzaman A, Tan PS, et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia [see comments]. Lancet. 1999;354:1257–1259. [PubMed]
49. Jahrling PB. Filoviruses and Arenaviruses. In: Murray PR, editor. Manual of Clinical Microbiology. Washington, D.C.: American Society for Microbiology; 1999. pp. 1125–1136.
50. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, et al. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis. 2003;188:1618–1629. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science